Desmoid Tumors Market, By Drug Type (Non-steroidal anti-inflammatory drugs(NSAIDs), Chemotherapy, Targeted Therapy, and Hormone Therapy), By Distribution channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4317
|
Published Date
August 2025
|
Pages
303
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.
Desmoid tumors are rare, benign (non-cancerous) growths that arise from connective tissue cells, usually within the fascia—the fibrous tissue surrounding muscles, nerves, and blood vessels. Although these tumors do not metastasize or spread to distant parts of the body like typical cancers, they are locally aggressive, meaning they can grow extensively and invade nearby tissues and structures. According to the National Organization for Rare Disorders (NORD), desmoid tumors affect approximately 2 to 4 individuals per million worldwide annually. Recognizing the impact of such rare diseases, governments globally are increasing funding for research and patient support programs, aiming to improve diagnosis, treatment options, and overall patient outcomes.
Desmoid Tumors Market- Market Dynamics
Rising Global Cancer Incidence Drives Growth in the Desmoid Tumor Market
The rising global incidence of cancer is expected to significantly contribute to the growth of the desmoid tumor market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and organs, leading to severe complications. As cancer cases increase worldwide, so does the demand for more effective and advanced chemotherapeutic agents—many of which are also used in managing desmoid tumors—thereby positively impacting market growth.
For example, in May 2024, the U.S. National Cancer Institute estimated that approximately 2,001,140 new cancer cases would be diagnosed in the United States in 2024, with 611,720 deaths expected due to the disease. Globally, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022. By 2040, the number of new cancer cases is projected to reach 29.9 million annually, with an estimated 15.3 million deaths. These alarming trends underscore the growing need for innovative therapies, including those for rare conditions like desmoid tumors, driving further growth in this market.
Desmoid Tumors Market- Segmentation Analysis:
The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.
The desmoid tumors market is segmented by drug type into five categories: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy, and Others. Among these, the chemotherapy segment is projected to be the largest in the global market by 2025 and is expected to maintain its dominance throughout the forecast period. Chemotherapy continues to be a critical treatment option for aggressive or inoperable desmoid tumors, despite its known systemic side effects. Recent advancements in combination drug regimens tailored to individual patient profiles have significantly improved both the efficacy and tolerability of chemotherapy. Additionally, ongoing clinical trials and research into novel chemotherapeutic agents with improved safety profiles are driving further growth in this segment. According to the National Cancer Institute (NCI), there are over 200 active clinical trials focused on soft tissue tumors in the U.S., many of which explore new chemotherapy approaches, reinforcing the sustained relevance of this treatment modality.
The market is also segmented by distribution channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with hospital pharmacies expected to hold the largest share of the global market during the forecast period. Hospital pharmacies play a crucial role in the treatment of desmoid tumors by ensuring timely access to essential medications for patients undergoing active care in clinical settings. They serve as a critical link between healthcare professionals and patients, facilitating both medication management and counseling services. This is particularly important for complex therapies like chemotherapy and targeted treatments, which often require close monitoring and adjustment. According to the American Society of Health-System Pharmacists (ASHP), over 90% of U.S. hospitals operate dedicated pharmacy departments that are directly involved in oncology treatment delivery, highlighting their significance in supporting treatment continuity and safety.
Desmoid Tumors Market- Geographical Insights
From a geographical perspective, North America represents the largest regional segment in the global desmoid tumors market and is expected to maintain its leadership position during the forecast period. Several factors contribute to this dominance, including rising healthcare expenditure, rapid adoption of advanced imaging technologies, a growing awareness of rare diseases, and an increasing incidence of desmoid tumors. The use of high-resolution MRI and CT scans has significantly enhanced tumor detection, location assessment, and monitoring capabilities. Data from the Centers for Medicare & Medicaid Services (CMS) reveals that healthcare spending in the U.S. reached nearly $4.7 trillion in 2023, with a considerable portion directed toward cancer diagnosis and treatment, underscoring the region\'s robust healthcare infrastructure.
In contrast, the Asia-Pacific region is projected to register the highest compound annual growth rate (CAGR) in the global desmoid tumors market over the forecast period. Factors driving this growth include a large and growing patient population, increased government investment in healthcare infrastructure, greater public awareness of rare diseases, and expanding access to medical services in emerging economies. Countries such as China and India are making significant strides in healthcare accessibility and innovation. According to the World Health Organization (WHO), healthcare spending in the Asia-Pacific region has grown at an annual rate of 6–7% over the past five years, with ongoing efforts to improve early diagnosis and treatment for rare and complex conditions, including desmoid tumors.
Desmoid Tumors Market- Competitive Landscape:
The desmoid tumors market is highly competitive, with both pharmaceutical companies and research institutions actively engaged in developing effective treatment options. Leading players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, the latter of which has participated in clinical trials for targeted therapies. In addition to established firms, smaller biotech companies and academic institutions are playing a significant role in advancing research and innovation.
Market competition is fueled by the urgent need to improve treatment outcomes, reduce adverse effects, and address unmet medical needs among patients. Efforts are focused on both developing novel therapies—such as targeted drugs and immunotherapies—and enhancing existing treatment regimens. Key factors influencing the competitive landscape include regulatory approvals, clinical trial outcomes, and the ability to secure intellectual property rights.
Recent Developments:
- In August 2023, Horizon Therapeutics Plc announced the U.S. launch of Krystexxa® (PEGylated brentuximab vedotin) for injection. The drug is approved for the treatment of adult patients with unresectable or recurrent, locally advanced or metastatic soft tissue sarcoma (STS), who have previously been treated with anthracycline-based chemotherapy.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Horizon Therapeutics Plc
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries Ltd
- Amneal Pharmaceuticals LLC
- Hikma Pharmaceuticals PLC
- Natco Pharma Ltd
- Lupin, Zydus Lifesciences
- Mylan N.V.
- Assertio Holdings, Inc.
- Mayne Pharma Group Limited
- Alembic Pharmaceuticals Limited, Aprazer
- Ayala Pharmaceuticals
- SpringWorks Therapeutics, Inc
- Iterion Therapeutics
- Novartis AG
- Apotex Inc.
- Bayer AG
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy\'s Laboratories Ltd
- Endo International plc
- Abbott
- Getwell Pharmaceuticals
- Others
GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- Non-steroidal anti-inflammatory drugs(NSAIDs)
- Chemotherapy
- Targeted Therapy
- Hormone Therapy
- Others
GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Desmoid Tumors Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Desmoid Tumors Market Snippet by Drug Type
2.1.2. Desmoid Tumors Market Snippet by Distribution channel
2.1.3. Desmoid Tumors Market Snippet by Country
2.1.4. Desmoid Tumors Market Snippet by Region
2.2. Competitive Insights
3. Desmoid Tumors Key Market Trends
3.1. Desmoid Tumors Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Desmoid Tumors Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Desmoid Tumors Market Opportunities
3.4. Desmoid Tumors Market Future Trends
4. Desmoid Tumors Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Desmoid Tumors Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Desmoid Tumors Market Landscape
6.1. Desmoid Tumors Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Desmoid Tumors Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
7.1.2. Non-steroidal anti-inflammatory drugs(NSAIDs)
7.1.3. Chemotherapy
7.1.4. Targeted Therapy
7.1.5. Hormone Therapy
7.1.6. Others
8. Desmoid Tumors Market – By Distribution channel
8.1. Overview
8.1.1. Segment Share Analysis, By Distribution channel, 2024 & 2032 (%)
8.1.2. Hospital Pharmacies
8.1.3. Retail Pharmacies
8.1.4. Online Pharmacies
9. Desmoid Tumors Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
9.2.1. Overview
9.2.2. Desmoid Tumors Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.5. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Desmoid Tumors Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.7. UK
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.7.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.7.4. UK Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.8. France
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.8.4. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.9. Italy
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.9.4. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.10. Spain
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.10.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.10.4. Spain Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.11. The Netherlands
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.11.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.11.4. The Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.12. Sweden
9.3.12.1. Overview
9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.12.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.13. Russia
9.3.13.1. Overview
9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.13.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.14. Poland
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.3.15. Rest of Europe
9.3.15.1. Overview
9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.3.15.4. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Desmoid Tumors Key Manufacturers in Asia Pacific
9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.5. APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.6. China
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.6.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.6.4. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.7. India
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.7.4. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.11. Indonesia
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.11.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.11.4. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.12. Thailand
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.12.4. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
9.5.1. Overview
9.5.2. Desmoid Tumors Key Manufacturers in Latin America
9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.5. LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
9.6.1. Overview
9.6.2. Desmoid Tumors Key Manufacturers in Middle East and Africa
9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.5. MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.7. UAE
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.7.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.7.4. UAE Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Desmoid Tumors Industry
10.1. Competitive Benchmarking
10.1.1. Competitive Dashboard
10.1.2. Competitive Positioning
10.2. Company Profiles
10.2.1. Horizon Therapeutics Plc
10.2.2. Strides Pharma Science Limited
10.2.3. Teva Pharmaceutical Industries Ltd
10.2.4. Amneal Pharmaceuticals LLC
10.2.5. Hikma Pharmaceuticals PLC
10.2.6. Natco Pharma Ltd
10.2.7. Lupin, Zydus Lifesciences
10.2.8. Mylan N.V.
10.2.9. Assertio Holdings, Inc.
10.2.10. Mayne Pharma Group Limited
10.2.11. Alembic Pharmaceuticals Limited, Aprazer
10.2.12. Ayala Pharmaceuticals
10.2.13. SpringWorks Therapeutics, Inc
10.2.14. Iterion Therapeutics
10.2.15. Novartis AG
10.2.16. Apotex Inc.
10.2.17. Bayer AG
10.2.18. Sun Pharmaceutical Industries Ltd
10.2.19. Dr. Reddy\'s Laboratories Ltd
10.2.20. Endo International plc
10.2.21. Abbott
10.2.22. Getwell Pharmaceuticals
10.2.23. Others
11. 360 Degree AnalystView
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
